PDF herunterladen
CC BY 4.0 · TH Open 2021; 05(03): e461-e469
DOI: 10.1055/a-1642-4572
Original Article

Prognostic Factors for Venous Thromboembolism in Patients with Solid Tumours on Systemic Therapy: A Systematic Review

Sandra Lee
1   Department of Surgery, McMaster University, Hamilton, Ontario, Canada
,
Anika Shenoy
2   Hamilton Health Sciences, Hamilton, Ontario, Canada
,
Daniel Shi
3   Department of Medicine, Queen's University, Kingston, Ontario, Canada
,
Mootaz Husien 
4   University of Waterloo, Waterloo, Ontario, Canada
,
Pablo E. Serrano
1   Department of Surgery, McMaster University, Hamilton, Ontario, Canada
,
Sameer Parpia
5   Department of Oncology, McMaster University, Hamilton, Ontario, Canada
6   Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
› Institutsangaben Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background Patients undergoing systemic cancer therapy are susceptible to developing venous thromboembolism (VTE). The most pertinent prognostic factors for VTE remain unclear. This systematic review aims to summarize prognostic factors associated with VTE in this population.

Methods MEDLINE, Embase, and CENTRAL databases were searched for observational or randomized studies that used multivariable analysis adjusted for tumor type and/or metastatic disease to model the risk of VTE. Adjusted effect estimates for each prognostic factor were collected for all of the included studies. Risk of bias was assessed using the Quality in Prognostic Factor Studies (QUIPS) tool.

Results From 5,988 search results, 15 eligible studies and 42 prognostic factors were identified. A total of 8,554 patients of whom 456 (5.33%) developed VTE were included. Fourteen studies had a high risk of bias and one study had a moderate risk. The most commonly reported prognostic factors include age, gender, tumor site, metastasis, performance status, and systemic therapy type. Poor performance status and the use of platinum-based chemotherapy compounds were associated with an increased risk of VTE across the majority of studies. The evidence to suggest that the other prognostic factors identified were associated with VTE development was inconclusive. Several individual studies identified novel biomarkers for VTE. Heterogeneity in statistical methods and prognostic factor definitions across studies precluded meta-analysis.

Conclusion Overall, many prognostic factors were identified; however, the evidence for association with development of VTE for most of the factors is inconclusive. Findings were limited by high heterogeneity and risk of bias in the included studies.

Keywords

venous thromboembolism - chemotherapy - neoplasms - prognosis

Author Contributions

Study concept and design: S Parpia, P Serrano, S Lee; Data acquisition: S Lee, A Shenoy; Data analysis and interpretation: All authors; Drafting and revising of the manuscript: All authors; Final approval of the manuscript version for publication: All authors.


Supplementary Material



Publikationsverlauf

Eingereicht: 27. April 2021

Angenommen: 07. September 2021

Accepted Manuscript online:
10. September 2021

Artikel online veröffentlicht:
23. November 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (03) 529-535
    CrossrefPubMedSuche in Google Scholar
  • 2 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (06) 809-815
    CrossrefPubMedSuche in Google Scholar
  • 3 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87 (04) 575-579
    Thieme ConnectPubMedSuche in Google Scholar
  • 4 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (04) 458-464
    CrossrefPubMedSuche in Google Scholar
  • 5 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedSuche in Google Scholar
  • 6 Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 2013; 18 (12) 1321-1329
    CrossrefPubMedSuche in Google Scholar
  • 7 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedSuche in Google Scholar
  • 8 Mulder FI, Candeloro M, Kamphuisen PW. et al; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 2019; 104 (06) 1277-1287
    CrossrefPubMedSuche in Google Scholar
  • 9 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
    CrossrefPubMedSuche in Google Scholar
  • 10 Barni S, Labianca R, Agnelli G. et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011; 9: 179
    CrossrefPubMedSuche in Google Scholar
  • 11 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151 (04) 264-9 , W64.
    CrossrefPubMedSuche in Google Scholar
  • 12 Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 2009; 22 (01) 9-23
    CrossrefPubMedSuche in Google Scholar
  • 13 Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013; 158 (04) 280-286
    CrossrefPubMedSuche in Google Scholar
  • 14 Ferroni P, Guadagni F, Laudisi A. et al. Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy. Oncologist 2014; 19 (05) 562-567
    CrossrefPubMedSuche in Google Scholar
  • 15 Ferroni P, Guadagni F, Riondino S. et al. Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica 2014; 99 (10) 1638-1644
    CrossrefPubMedSuche in Google Scholar
  • 16 Ferroni P, Palmirotta R, Riondino S. et al. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. Thromb Haemost 2016; 115 (01) 143-151
    Thieme ConnectPubMedSuche in Google Scholar
  • 17 Ferroni P, Riondino S, Formica V. et al. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer 2015; 136 (05) 1234-1240
    CrossrefPubMedSuche in Google Scholar
  • 18 Roselli M, Ferroni P, Riondino S. et al. Impact of chemotherapy on activated protein C-dependent thrombin generation–association with VTE occurrence. Int J Cancer 2013; 133 (05) 1253-1258
    CrossrefPubMedSuche in Google Scholar
  • 19 Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104 (12) 2822-2829
    CrossrefPubMedSuche in Google Scholar
  • 20 van Es N, Di Nisio M, Cesarman G. et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017; 102 (09) 1494-1501
    CrossrefPubMedSuche in Google Scholar
  • 21 van Es N, Hisada Y, Di Nisio M. et al. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study. Thromb Res 2018; 166: 54-59
    CrossrefPubMedSuche in Google Scholar
  • 22 Di Nisio M, van Es N, Rotunno L. et al. Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis 2019; 48 (01) 125-133
    CrossrefPubMedSuche in Google Scholar
  • 23 Abdel-Razeq H, Mansour A, Abdulelah H. et al. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!. Thromb J 2018; 16: 2
    CrossrefPubMedSuche in Google Scholar
  • 24 Tafur AJ, Dale G, Cherry M. et al. Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. Thromb Res 2015; 136 (06) 1120-1125
    CrossrefPubMedSuche in Google Scholar
  • 25 Arpaia G, Carpenedo M, Verga M. et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 2009; 20 (03) 170-175
    CrossrefPubMedSuche in Google Scholar
  • 26 Vergati M, Della-Morte D, Ferroni P. et al. Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer. Rejuvenation Res 2013; 16 (03) 224-231
    CrossrefPubMedSuche in Google Scholar
  • 27 Gerotziafas GT, Taher A, Abdel-Razeq H. et al; COMPASS–CAT Working Group. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist 2017; 22 (10) 1222-1231
    CrossrefPubMedSuche in Google Scholar
  • 28 Bosch FTM, Mulder FI, Kamphuisen PW. et al. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv 2020; 4 (20) 5215-5225
    CrossrefPubMedSuche in Google Scholar
  • 29 Doggen CJ. Thromboprophylaxis in cancer outpatients. Blood 2008; 111 (10) 4833
    CrossrefPubMedSuche in Google Scholar
  • 30 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (03) 291-292
    CrossrefPubMedSuche in Google Scholar
  • 31 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (06) 715-722
    CrossrefPubMedSuche in Google Scholar
  • 32 Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006; 118 (05) 555-568
    CrossrefPubMedSuche in Google Scholar
  • 33 Elliott MA, Wolf RC, Hook CC. et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004; 45 (08) 1545-1549
    CrossrefPubMedSuche in Google Scholar
  • 34 Dickmann B, Ahlbrecht J, Ay C. et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98 (08) 1309-1314
    CrossrefPubMedSuche in Google Scholar
  • 35 Alahmari AK, Almalki ZS, Alahmari AK, Guo JJ. Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials. Am Health Drug Benefits 2016; 9 (04) 221-232
    PubMedSuche in Google Scholar
  • 36 Li LJ, Chen DF, Wu GF. et al. Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma. J Thorac Dis 2018; 10 (08) 5010-5022
    CrossrefPubMedSuche in Google Scholar
  • 37 Numico G, Garrone O, Dongiovanni V. et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103 (05) 994-999
    CrossrefPubMedSuche in Google Scholar
  • 38 Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008; 7 (06) 703-716
    CrossrefPubMedSuche in Google Scholar